A Medical Device Daily
CSMG Technologies (Corpus Christi, Texas) said it has received approval of its fifth U.S. patent. The approval is on a key divisional application for "Bonding of Soft Biological Tissues by Passing High-Frequency Electric Current Therethrough" for subsidiary Live Tissue Connect's (LTC) platform tissue bonding/welding technology.
The patent approval follows the issuance of four other U.S. patents, a European Union patent in eight European countries, Ukraine, Canada and Australia, with 14 U.S. and international patents pending.
Donald Robbins, president/CEO of CSMG Technologies, said, "This U.S. patent approval re-enforces our patent portfolio and expands LTC's commercial possibilities while increasing our shareholder value."
He added, "Our strong patent portfolio and a disruptive technology, as well as ISO 13485:2003 certification for the design and manufacture of Bipolar Forceps Systems, recent FDA 510(k) clearance and European Union CE-mark certification on LTC's VAD.400 electrosurgery generator and two instruments puts us in an excellent position of competing in global medical device markets."
LTC's surgical tissue bonding / welding device is a platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound-closing devices such as sutures, staples, sealant or glues.
LTC currently holds a total of some 31 patents and pending patents in the U.S., Australia, Canada, the European Union, Ukraine and other countries.